Rapalink-1, a dual mTOR inhibitor, significantly reduced cellular senescence markers including SA-β-gal positivity, DNA damage (γ-H2AX and 8-OHDG), and inflammatory factor expression in human vascular cells exposed to oxidative stress. The compound also decreased phosphorylation of key aging-related proteins p65, p38, and ERK1/2, suggesting multi-pathway protection against vascular deterioration. This represents a potentially important advance in vascular aging research, as mTOR inhibition has emerged as one of the most promising longevity interventions across species. Unlike rapamycin, which only inhibits mTORC1, Rapalink-1 targets both mTORC1 and mTORC2 complexes, potentially offering broader protective effects. The findings are particularly relevant given that vascular senescence drives cardiovascular disease, the leading cause of death globally. However, this remains early-stage laboratory research using cultured human cells under artificial stress conditions. The oxidative stress model, while useful, may not fully replicate the complex aging processes in living blood vessels. Translation to human therapeutics requires extensive safety testing, as mTOR inhibition can impair immune function and wound healing.